Percent of peripheral blood lymphocytes expressing CD25 before and after DAB₃₈₉IL-2 administration (patients without circulating malignant cells, HD = 21; NHL = 11; CTCL = 8). (•) CD25; (⧫) CD3/25; (▿) CD4/25; (□) CD8/25.